[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369395-105":59,"doc-detail-369395-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","assessment-of-lncrna-biomarkers-based-on-nets-for-prognosis-and-therapeutic-response-in-ovarian-cancer","Assessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer","","Ovarian cancer often progresses rapidly and lacks reliable clinical factors for accurate prognosis prediction. Neutrophil extracellular traps (NETs) have been increasingly recognized for their pathogenic roles across cancers, including ovarian cancer. This study builds a prognosis model using six NETs-related lncRNAs selected by LASSO and identifies key prognostic features with univariate and multivariate Cox regression. Predictive performance is evaluated with Kaplan–Meier, ROC, and Cox analyses, and mechanisms are explored via GO, KEGG, and GSEA, along with mutation and survival analyses. Immune characteristics, checkpoint expression, and chemotherapy sensitivity are compared between risk groups, with validation using institutional test data and tissues and in vitro/in vivo experiments to confirm lncRNA expression and GAS5 function.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessment-of-lncrna-biomarkers-based-on-nets-for-prognosis-and-therapeutic-response-in-ovarian-cancer/369395/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessment-of-lncrna-biomarkers-based-on-nets-for-prognosis-and-therapeutic-response-in-ovarian-cancer/369395.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study in ovarian cancer?","Question",{"text":112,"@type":113},"To determine whether NETs-related biomarkers can accurately predict prognosis and support clinical decision-making for ovarian cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the six NETs-related lncRNAs selected for the prognostic model?",{"text":117,"@type":113},"The study used univariate and multivariate Cox regression to identify prognostic features, and LASSO regression to select six NETs-related lncRNAs for the risk model.",{"name":119,"@type":110,"acceptedAnswer":120},"What analyses were used to assess the model’s predictive performance?",{"text":121,"@type":113},"Predictive capability was evaluated using Kaplan–Meier, ROC, and Cox analyses, and model mechanisms were explored with GO, KEGG pathway enrichment, and GSEA.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369395,1790210692,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAssessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer  \nJingmeng Wang1,2, Yusen Liang1,2, Yimei Meng1,2, Jialin Chen1,2, Lei Fang1, Huike Yang2,3􀀍 & Peiling Li1􀀍  \nOvarian cancer (OC) usually progresses rapidly and is associated with high mortality, while a reliable clinical factor for OC patients to predict prognosis is currently lacking. Recently, the pathogenic role of neutrophils releasing neutrophil extracellular traps (NETs) in various cancers including OC has gradually been recognized. The study objective was to determine whether NETs-related biomarkers can be used to accurately predict the prognosis and guide clinical decision-making in OC. In this study, we utilized univariate and multivariate Cox regression to identify key prognostic features and developed a model with six NETs-related lncRNAs, selected via LASSO regression. The model’s predictive capability was assessed through Kaplan–Meier, ROC, and Cox analyses. To understand the model’s mechanisms, we conducted GO term analysis, KEGG pathway enrichment, and GSEA. We also analyzed gene mutation status, tumor mutation load, survival rates, and model correlation. Additionally, we compared immune functions, immune checkpoint expression, and chemotherapy sensitivity between risk groups. Besides, we validated the model’s predictive value using test data and tissues acquired from our institution. Finally, we performed in vitro and in vivo experiments to confirm the expression of model lncRNAsand the cellular level function of GAS5. We developed a model using six NETs-associated lncRNAs:  \nGAS5, GBP1P1, LINC00702, LINC01933, LINC02362, and ZNF687-AS1. The model’s predictive performance, evaluated via ROC curve, was compared with traditional clinicopathological features. GO process analysis highlighted molecular functions related to antigen binding and immune system biological processes. Variations were observed in transcription regulators affecting immune response, inflammation, cytotoxicity, and regulation. We also predicted IC50 values for chemotherapeutic drugs (bexarotene, bicalutamide, embelin, GDC0941, and thapsigargin) in high-and low-risk groups, finding higher IC50 values in low-risk patients. The risk model’s robustness was validated using OC cells, tissues, and clinical datas.  \nKeywords Neutrophil extracellular traps (NETs), LncRNA, Ovarian cancer, Prognosis, Targeted therapy  \nEpithelial ovarian cancer, which constitutes approximately 90% of all ovarian cancer cases, ranks as the third most prevalent gynecological malignancy and is the leading cause of gynecologic cancer-related mortality1,2. The primary reason for the high mortality rate is the extensive metastatic spread, primarily in the abdomen. The standard approach for treating patients with advanced epithelial ovarian cancer remains cytoreductive surgery and platinum-based chemotherapy3. Although the majority of patients with advanced stage disease (i.e., stage III-IV) initially respond to front-line therapy consisting of cytoreductive surgery and platinum-based chemotherapy, 60–80% of patients with advanced disease will experience recurrence4. In most cases, cancer recurrence occurs at progressively shorter intervals, and patients eventually develop drug resistance. Currently, the five-year survival rates for patients with advanced ovarian cancer remain below 50%5. This indicates that existing prognostic and predictive tools based on standard clinicopathological factors are still insufficient to accurately guide clinical decision-making. Therefore, there is a need for new biomarkers to predict the prognosis and drug sensitivity of ovarian cancer patients.  \n1Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Harbin Medical University, Harbin, China. 2Laboratory of Department of Anatomy, Harbin Medical University, Harbin, China. 3Key Laboratory of Pre","cbCaijM5rZP1mRTK","https://ap.wps.com/l/cbCaijM5rZP1mRTK","pdf",7457546,15,"English","# Introduction\n## Clinical need and recurrence in ovarian cancer\n## NETs biology and rationale\n## NETs composition and therapeutic targeting\n# Methods\n## Biomarker selection and model construction\n## Statistical evaluation and mechanism analysis\n## Immune and drug sensitivity comparisons\n## Validation and experimental confirmation\n# Results\n## Six-lncRNA NETs-related prognostic model\n## Functional enrichment and transcription regulator differences\n## Immune checkpoint and chemotherapy sensitivity between risk groups\n## Robustness validation in cells, tissues, and clinical data\n# Discussion","[{\"question\":\"What is the main goal of this study in ovarian cancer?\",\"answer\":\"To determine whether NETs-related biomarkers can accurately predict prognosis and support clinical decision-making for ovarian cancer patients.\"},{\"question\":\"How were the six NETs-related lncRNAs selected for the prognostic model?\",\"answer\":\"The study used univariate and multivariate Cox regression to identify prognostic features, and LASSO regression to select six NETs-related lncRNAs for the risk model.\"},{\"question\":\"What analyses were used to assess the model’s predictive performance?\",\"answer\":\"Predictive capability was evaluated using Kaplan–Meier, ROC, and Cox analyses, and model mechanisms were explored with GO, KEGG pathway enrichment, and GSEA.\"}]","Assessment of lncRNA biomarkers based on NETs for prognosis and therapeutic response in ovarian cancer | PDF",1790182422,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e8af12a64b3f672112035bf36e6e2cf.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa652670f45769ec62a471a748f53afc.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df8132cebed903de77eaa84ecdb26811.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f1336ec2cf01c42e788e79806fc5e57.webp",980,1287]